Fifteen years ago, small molecules (chemically synthesised molecules designed to interact with a specific cellular receptor) represented the majority of pharmaceuticals under development. During the past ten years, however, the number of therapies being developed that fall into the broad category of biopharmaceuticals has exploded, and there are predictions that the majority of therapies developed in the next ten years will fall into this class.